Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PE Biosystems (PEB) -- Ignore unavailable to you. Want to Upgrade?

To: Ken Robbins who wrote (14)	1/28/1998 8:51:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 122

Zack's number was $0.86, indicating a miss of about 4 cents. Revenues were up only about 4% over year ago. Appeared to blame the miss on currency translations. ABI division up about 13%, indicating other sales not so good. On first glance, results look disappointing to me.

To: Ken Robbins who wrote (14)	1/28/1998 10:03:00 AM
From: Don Dorsey	Respond to of 122

I follow PKN because it is one of the few blue chip companies involved in the biotech sector. Biotech and genetic engineering are very exciting areas, with enormous potential, but most companies in the industry are highly speculative, with little or no earnings, and dependent on one or several products. PKN is a large, well diversified company, which can participate in the growth of the industry while bringing the advantage of great financials. I also like the fact that PKN is dependent on continued equipment sales, not on cures or breakthroughs. People will continue to buy equipment, because of the great potential if their research is successfull, but it might take years before there are any breakthroughs.